Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Natural Killer (NK) Cell Therapeutics Market to Perceive Healthy CAGR of 40.9% by 2029, Size, Share, Trends, Demand, Opportunities, Challenges and Competitive Analysis

Published

on

 

Data Bridge Market Research completed a qualitative study titled “Natural Killer (NK) Cell Therapeutics Market” with 100+ market data tables, pie charts, graphs, and figures spread across Pages and an easy to grasp full analysis. By keeping into focus customer requirements, an influential Natural Killer (NK) Cell Therapeutics market analysis report has been generated by chewing over quite a lot of market parameters. These factors consist of but are not limited to latest trends, market segmentation, new market entry, industry forecasting, future directions, opportunity identification, strategic analysis and planning, target market analysis, insights and innovation. For market segmentation study conducted in the large scale Natural Killer (NK) Cell Therapeutics report, the market of potential customers is divided into groups or segments based on different characteristics such as application of product, deployment model, end user and geographical region etc.

Global natural killer (NK) cell therapeutics market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that global natural killer (NK) cell therapeutics market will grow at a CAGR of 40.9% during the forecast period of 2022 to 2029.

Download Sample Copy of Natural Killer (NK) Cell Therapeutics Market Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-natural-killer-nk-cell-therapeutics-market

Market Overview:

Natural killer (NK) cells therapeutics report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. Contact us for an analyst brief to understand the analysis and the market scenario; our team will help you create a revenue impact solution to achieve your desired goal. An increase in the usage of natural killer cells for the treatment of infectious diseases is the major driver that propelled the market’s demand in the forecast period.

Global natural killer (NK) cell therapeutics comprises features such as an increasing need for better therapeutics options that will impair the manufacturers’ launching new products into the market, enhancing its increased demand investment in research and development leads to the market growth. Currently, various research studies are taking place, which is expected to create a competitive advantage for manufacturers to develop new and innovative natural killer (NK) cell therapeutics that will provide various other opportunities in the natural killer (NK) cells therapeutics market. However, adverse side effects of therapies and unfavorable & inadequate reimbursement scenarios are expected to restrain the market growth in the forecast period.

Opportunities for Players:

  • Strategic Initiatives by Market Players

Market players adopt various strategic initiatives that involve expansion, acquisition, and collaboration, among others. These initiatives help them increase the company’s product portfolio, leading to market expansion and, hence, enhancing the product demand among customers, ultimately leading the players to earn maximum revenue.

As the demand for effective and affordable natural killer (NK) cell immunotherapy is increasing worldwide, these strategic initiatives are taken by top market players aimed at enhancing business operations and earning more profitability in the market.

Some of the major players operating in the Natural Killer (NK) Cell Therapeutics market are:

  • Merck KGaA,
  • Bristol-Myers Squibb Company,
  • Glycostem,
  • Kiadis Pharma,
  • Cytovia Therapeutics,
  • Nkarta, Inc.,
  • Nektar,
  • ImmunityBio, Inc.,
  • Brink Biologics, Inc.,
  • Biohaven Pharmaceuticals,
  • Fate Therapeutics,
  • EMERcell,
  • Phio Pharmaceuticals,
  • PersonGen BioTherapeutics,
  • Innate Pharma, Inc.,
  • INmuneBIO,
  • Gamida Cell,
  • Acepodia Inc.,
  • Affimed GmbH,
  • Multimmune GmbH,
  • iCell Gene Therapeutics,
  • Takeda Pharmaceutical Company Limited,
  • Regeneron Pharmaceuticals

Get Full Research Report to Understand More @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-natural-killer-nk-cell-therapeutics-market

Recent Developments

  • In January 2022Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors.  Through the acquisition, Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programs. Adaptate’s γδ T cell engagers are designed to specifically modulate γδ T cell-mediated immune responses at tumor sites while sparing damage to healthy cells. This acquisition help the company to to focus on R&D.
  • In December 2021Nektar Therapeutics announced phase 1b data for novel T regulatory cell stimulator NKTR-358 (LY3471851) in patients with atopic dermatitis. NKTR-358 is designed to treat autoimmune and inflammatory conditions by correcting the immune system imbalance that results from increased levels of inflammatory T cells and reduced numbers and impaired function of immune regulating Treg cells. This has helped company to focus on R&D for further phases.

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Natural Killer (NK) Cell Therapeutics market

Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the market

Competitive Assessment: In-depth assessment of the market strategies, and geographic and business segments of the leading players in the market

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Natural Killer (NK) Cell Therapeutics Market

THANKSGIVING WEEK SALE!!!

Get UP TO 35%. OFF ON GLOBAL REPORTS. OFFER VALID TILL 30th NOV 2022

For More, Inquire at https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-natural-killer-nk-cell-therapeutics-market

Market Dynamics: Natural Killer (NK) Cell Therapeutics Market

  • Increase in Patient Population with Chronic Diseases

Chronic diseases generally occur in older adults that can be controlled but not cured, such as heart disease, arthritis, diabetes, stroke, or cancer. Chronic diseases are a worldwide healthcare problem concern. The change in lifestyle and physical inactivity, unhealthy diet, and tobacco use increase the burden of chronic diseases worldwide.

An increasing number of the patient population with the chronic disease led the scientist and researchers to work upon the new innovative therapeutic approach to provide patients with the best curative treatment option, which can be achieved by using natural killer (NK) cell therapy that has the potential to generate a strong immune response and has the anti-tumor capability as well.

  • Rise in Awareness about Immunotherapies

As cancer is a devastating disease and available treatment options may cause the reoccurrence of tumors, the need for the best therapeutic approach is increasing day by day. Immunotherapies have attracted much attention in recent years to treat various malignancies. Among the immunotherapies, CAR –T cell therapies have been studied and were used but have several limitations that led to the development of natural killer (NK) cell therapies. As a drug based on the natural killer (NK) cell therapeutic approach has not been approved yet, it thus needs to raise awareness among the population.

This is why several organizations and market players are launching a campaign to enhance natural killer (NK) cell therapies awareness.

Consider Data Bridge Market Research for this Report which would Help Impact Your Revenues Positively

  • This study offers the latest product news, trends, and updates from the industry’s leading players who have leveraged their market position.
  • It also offers strategic plans and standards to arrive at informed business decisions adopted by the main players, thereby advocating your go to market strategies.
  • In addition, it offers insights into the dynamics of customer behaviour that can help the organization better curate market strategies
  • Usage of exclusive tailor-made tools along with primary research, secondary research and our in-house data model helps us in extracting the exact market numbers
  • Mapping the customer in 3P grid comprising of Purpose, Planning and Positioning, thereby delivering a solution by keeping the prospecting client at the sweet spot
  • The Natural Killer (NK) Cell Therapeutics market research report includes all of the market’s valuable elements, such as sales growth, product pricing & analysis, growth opportunities, and recommendations for addressing market challenges
  • The report covers all the primary mergers & acquisitions, alliances, and collaborations that have generated additional opportunities for market players or in some cases, challenges

To Gain More Insights about this Research, Visit @ https://www.databridgemarketresearch.com/reports/global-natural-killer-nk-cell-therapeutics-market

Key Industry Segmentation: Natural Killer (NK) Cell Therapeutics Market

By Therapeutics

  • NK Cell Therapies
  • NK Cell Directed Antibodies

By Approaches

  • Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
  • Bispecific Antibodies

By Application

By End User

  • Research & Academic Institutes
  • Hospitals
  • Specialty Clinics

By Distribution Channel

  • Hospital Pharmacies
  • Direct Tender

Regional Analysis/Insights: Natural Killer (NK) Cell Therapeutics Market

The countries covered in the natural killer (NK) cell therapeutics market report are U.S., CanadaMexicoGermanyFranceItaly, U.K., SpainNetherlandsRussiaSwitzerlandTurkeyAustriaNorwayHungaryLithuaniaIrelandPolandLuxembourg , Rest of EuropeJapanChinaIndiaSouth KoreaAustraliaSingaporeMalaysiaThailandIndonesiaPhilippinesVietnam, Rest of Asia-Pacific , BrazilArgentinaPeru, Rest of South AmericaSaudi ArabiaSouth Africa, UAE, IsraelKuwaitEgypt, Rest of Middle East & Africa.

Asia-Pacific is expected to dominate due to increase in usage of natural killer (NK) cells for the treatment of cancer and infectious diseases.

Table of Contents:

  1. Introduction
  2. Market Segmentation
  3. Executive Summary
  4. Premium Insights
  5. Global Natural Killer (NK) Cell Therapeutics Market: Regulations
  6. Market Overview
  7. Global Natural Killer (NK) Cell Therapeutics Market, By Therapeutics
  8. Global Natural Killer (NK) Cell Therapeutics Market, By Approaches
  9. Global Natural Killer (NK) Cell Therapeutics Market, By Application
  10. Global Natural Killer (NK) Cell Therapeutics Market, By End User
  11. Global Natural Killer (NK) Cell Therapeutics Market, By Distribution Channel
  12. Global Natural Killer (NK) Cell Therapeutics Market, By Region
  13. Global Natural Killer (NK) Cell Therapeutics Market: Company Landscape
  14. SWOT Analyses
  15. Company Profile
  16. Questionnaires
  17. Related Reports

To Check the Complete Table of contents, click here @ https://www.databridgemarketresearch.com/toc/?dbmr=global-natural-killer-nk-cell-therapeutics-market

Explore More Reports:

Europe Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Immunoproliferative Disorders, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others) https://www.databridgemarketresearch.com/reports/europe-natural-killer-nk-cell-therapeutics-market

North America Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Immunoproliferative Disorders, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others) https://www.databridgemarketresearch.com/reports/north-america-natural-killer-nk-cell-therapeutics-market

Asia-Pacific Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Immunoproliferative Disorders, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others) https://www.databridgemarketresearch.com/reports/asia-pacific-natural-killer-nk-cell-therapeutics-market

Middle East and Africa Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Immunoproliferative Disorders, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others) https://www.databridgemarketresearch.com/reports/middle-east-and-africa-natural-killer-nk-cell-therapeutics-market

Health Tourism Market, By Service (Transport, Accommodation, Hospitality and Others), Type of Treatment (Cosmetic Treatment, Dental Treatment, Cardiovascular Treatment, Orthopaedic Treatment, Bariatric Treatment, Fertility Treatment, Cancer Treatment, Ophthalmic Treatment, Neurological Treatment and Others), Age Group (Senior Citizens, Minors and Adults), By Service Provider (Private and Public) https://www.databridgemarketresearch.com/reports/global-health-tourism-market

Nanomedicine Market, By Product Type (Nano Molecules, Nanoparticles, Liposomes, Polymer And Polymer Drug Conjugates, Hydrogel Nanoparticles, Dendrimers, Nanoshells, Nanotubes And Nanodevices), Application (Vaccines, Regenerative Medicines, Diagnostic Imaging, Drug Delivery, Implants, In-Vitro Imaging, In-Vitro Diagnostics, Therapeutics And Others), Indication (Oncological Diseases, Infectious Diseases, Cardiovascular Diseases, Orthopedic Disorders, Neurological Disorders, Urological Disorders, Ophthalmological Diseases, Immunological Diseases, Anti-Inflammatory Diseases, Anti-Infective Diseases And Others) Modality (Treatments And Diagnostics), And Country https://www.databridgemarketresearch.com/reports/global-nanomedicine-market

eHealth Market, By Offering (Solutions and Services), Deployment (Cloud and On-Premises), Enterprise Size (Large Enterprises and Small and Medium Enterprises), Functionality (Content Management System, Group Messaging, Dashboard, Video Sessions, Social Support, and Others), Technology (Internet of Things (IoT), Chatbots, Artificial Intelligence, Block Chain and Big Data, and Others), End User (Healthcare Providers, Payers, Healthcare Consumers, Pharmacies, and Others) https://www.databridgemarketresearch.com/reports/global-ehealth-market

Healthcare Information Technology (IT) Market, By Product and Services (Healthcare Provider Solutions, Healthcare Payer Solutions, Healthcare Information Technology Outsourcing Services), Components (Services, Software, Hardware), Delivery Mode (On-Premise, Cloud-Based), End-Users (Providers, Payers) https://www.databridgemarketresearch.com/reports/global-healthcare-it-market

Diabetes Care Devices Market, By Product (Blood Glucose Monitoring Device, Insulin Delivery Devices), End User (Point of Care, Home Diagnostics, Research Labs, Hospital and Clinics), Country https://www.databridgemarketresearch.com/reports/global-diabetes-care-devices-market

Artificial Intelligence

Aetina Accelerates Embedded AI with High-performance, Small Form-factor Aetina IA380E-QUFL Graphics Card

Published

on

aetina-accelerates-embedded-ai-with-high-performance,-small-form-factor-aetina-ia380e-qufl-graphics-card

TAIPEI, April 25, 2024 /PRNewswire/ — Aetina, a leading Edge AI solution provider, announced the launch of the Aetina IA380E-QUFL at Embedded World 2024 in Nuremberg, Germany. This groundbreaking product is a small form factor PCIe graphics card powered by the high-performance Intel Arc A380E GPU. 

Unmatched Power in a Compact Design
The Aetina IA380E-QUFL delivers workstation-level performance packed into a low-profile, single-slot form factor. This innovative solution consumes only 50W, making it ideal for space and power-constrained edge computing environments. Embedded system manufacturers and integrators can leverage the power of 4.096 TFLOPs peak FP32 performance delivered by the Intel Arc A380E GPU[1].
Beyond Small Size: Big Capabilities
Despite its compact size, the IA380E-QUFL offers native support for 4 mini-DisplayPort outputs and 6GB of GDDR6 memory, enabling the connection of multiple high-resolution displays (UHD). This makes the IA380E-QUFL an excellent choice for a wide range of applications, including commercial gaming, video walls, medical imaging, and visual inference for smart cities.
“The demand for slim and energy-efficient AI systems is rapidly escalating,” said Jackal Chen, Senior Product Manager at Aetina. “The Aetina IA380E-QUFL addresses this need head-on, offering a powerful GPU solution in a compact, single-slot form factor with minimal power consumption. This empowers developers to create powerful and efficient edge systems for a wide range of applications.”.
Unparalleled Commitment: 5-Year Product Supply
Acknowledging the critical need for long-term product stability in industrial applications, Aetina ensures a 5-year product supply for the Aetina IA380E-QUFL, which streamlines system roadmaps and reduces the need for costly redesign. Our commitment is aligned with Intel’s announced product plans for the Intel Arc A380E GPU.[1]
[1]https://www.intel.com/content/www/us/en/content-details/820389/intel-arc-gpu-for-the-edge-public-30-3-30.html?wapkw=Intel%20Arc%20GPU%2030-3-30&DocID=820389 Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.
Photo –  https://mma.prnewswire.com/media/2395995/High_performance_Small_Form_factor_Aetina_IA380E_QUFL_Graphics_Card.jpg

View original content:https://www.prnewswire.co.uk/news-releases/aetina-accelerates-embedded-ai-with-high-performance-small-form-factor-aetina-ia380e-qufl-graphics-card-302125786.html

Continue Reading

Artificial Intelligence

IG Canada Announces Enhanced Trading Platform for Enhanced User Experience

Published

on

ig-canada-announces-enhanced-trading-platform-for-enhanced-user-experience

Meta description : Explore IG Canada’s advanced trading platform, educational resources, and robust security features. Achieve your trading goals with the innovative tools.
NOTTINGHAM, England, April 25, 2024 /PRNewswire/ — IG Canada, a premier online trading platform, is pleased to announce significant enhancements to its trading technology, designed to empower both novice and experienced traders with superior tools and resources. This development is part of IG Canada’s commitment to providing the best trading experience in the Canadian market.

IG Canada has upgraded its platform with advanced features that streamline trading processes and improve the accuracy of trade execution. These enhancements include customizable charts, a wider range of indicators, and improved mobile access, ensuring traders can operate efficiently from anywhere at any time.
Recognizing the importance of education in trading success, IG Canada has expanded its educational resources. The brokerage now offers a comprehensive learning center featuring webinars, tutorials, and articles that cater to various skill levels. These resources are designed to help traders develop robust trading strategies and improve their market knowledge.
Security remains a top priority for IG Canada. The latest updates include enhanced encryption and multi-factor authentication to protect client data and funds. These security measures provide peace of mind for traders, knowing their investments are safeguarded against potential threats.
IG Canada is a leading online brokerage that provides trading services across multiple asset classes, including forex, stocks, commodities, and indices. With a focus on innovation and customer service, IG Canada is committed to helping Canadian traders achieve their investment goals through a transparent and efficient trading environment.
In addition, IG Canada is committed to engaging with the community through upcoming webinars, live events, and partnerships with local financial experts. These initiatives are designed not only to support the growth and education of the clients but also to foster a stronger, more connected trading community in Canada.
Press Contact:Contact Name: Timothy C. SherwinEmail: [email protected] Phone: +447 441425053

View original content:https://www.prnewswire.co.uk/news-releases/ig-canada-announces-enhanced-trading-platform-for-enhanced-user-experience-302127189.html

Continue Reading

Artificial Intelligence

Sentrycs Now Part of the UK National Protective Security Authority Catalog of Security Equipment

Published

on

sentrycs-now-part-of-the-uk-national-protective-security-authority-catalog-of-security-equipment

This inclusion into the NPSA CSE marks a significant milestone in the company’s commitment to enhancing national and international airspace security and to leading the C-UAS market toward multi-layer strategy optimization and excellence.
TEL-AVIV, Israel, April 25, 2024 /PRNewswire/ — Sentrycs, a leading innovator in adaptive counter-drone solutions, is proud to announce its inclusion in the prestigious UK National Protective Security Authority Catalogue of Security Equipment (NPSA CSE).
 
Following a rigorous assessment process, Sentrycs’ cutting-edge Counter Unmanned Aerial Systems (C-UAS) solution has met the high standards set by the NPSA for Detection, Tracking, and Identification (DTI). The testing, conducted at the NPSA’s designated testing facilities in August 2023, rigorously evaluated the Sentrycs system against the NPSA’s DTI Testing and Evaluation Standard v3.1.
Sentrycs elected to be assessed under Configuration D as a 3D system with Ground Control Station (GCS) detection capability and platform identification capability, which is the most demanding test scenario with the highest number of scored parameters.
The Sentrycs system demonstrated exceptional capabilities in various security scenarios, showcasing its robustness in detecting and tracking with high accuracy and zero false alarms. The system’s innovative use of cyber techniques to extract data from targets and its streamlined human-machine interface were especially noted for their efficiency and ease of use.
“Our team is proud to have Sentrycs recognized by the UK National Protective Security Authority,” said Yoav Zaltzman, CEO of Sentrycs. “Being listed in the CSE is not just an honor; it’s a testament to our technology’s reliability and effectiveness in contributing to the ever-changing airspace security landscape.”
Sentrycs’ technology is now accessible through the NPSA CSE, providing security practitioners with verified solutions that meet the UK’s rigorous security standards. This inclusion not only underscores Sentrycs’ role in advancing security technology but also enhances its visibility and credibility on a global stage.
For more details on Sentrycs’ solutions and their impact, visit www.sentrycs.com.
For further information regarding the NPSA and the Catalog of Security Equipment, please visit the NPSA’s official website.
About Sentrycs
Sentrycs is a leader in adaptive counter-drone solutions, supported by innovative technology designed to passively identify, mitigate, and where necessary, intercept unauthorized drones custom-built for various environments – including airports, borders, prisons, critical infrastructure, and mass events. Founded in 2017, Sentrycs’ has offices in Israel and the US, serving customers worldwide. By uniting its field-proven technology and expertise in global drone environments, Sentrycs is leading the way towards a safer and more secure drone-driven future. Learn more at www.sentrycs.com
Video – https://www.youtube.com/watch?v=YBuhpTq5QuM

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/sentrycs-now-part-of-the-uk-national-protective-security-authority-catalog-of-security-equipment-302126952.html

Continue Reading

Trending